questionsmedicales.fr
Environnement et santé publique
Santé publique
Accidents
Prévention des accidents
Sécurité
Gestion de la sécurité
Fiches techniques sur la sécurité des substances
Fiches techniques sur la sécurité des substances : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fiches techniques sur la sécurité des substances : Questions médicales les plus fréquentes",
"headline": "Fiches techniques sur la sécurité des substances : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fiches techniques sur la sécurité des substances : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-30",
"dateModified": "2025-03-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fiches techniques sur la sécurité des substances"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gestion de la sécurité",
"url": "https://questionsmedicales.fr/mesh/D017751",
"about": {
"@type": "MedicalCondition",
"name": "Gestion de la sécurité",
"code": {
"@type": "MedicalCode",
"code": "D017751",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N06.850.135.060.075.800"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Fiches techniques sur la sécurité des substances",
"alternateName": "Material Safety Data Sheets",
"code": {
"@type": "MedicalCode",
"code": "D063967",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "So Mi Jemma Cho",
"url": "https://questionsmedicales.fr/author/So%20Mi%20Jemma%20Cho",
"affiliation": {
"@type": "Organization",
"name": "Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "Hokyou Lee",
"url": "https://questionsmedicales.fr/author/Hokyou%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "Jongmin Baek",
"url": "https://questionsmedicales.fr/author/Jongmin%20Baek",
"affiliation": {
"@type": "Organization",
"name": "Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "Hyeon Chang Kim",
"url": "https://questionsmedicales.fr/author/Hyeon%20Chang%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "Lisa-Maria Wittmann",
"url": "https://questionsmedicales.fr/author/Lisa-Maria%20Wittmann",
"affiliation": {
"@type": "Organization",
"name": "Department of Mechanical Engineering, Institute of Polymer Technology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Am Weichselgarten 10, 91058 Erlangen, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.",
"datePublished": "2024-10-31",
"url": "https://questionsmedicales.fr/article/39482761",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13075-024-03418-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37098795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42510"
}
},
{
"@type": "ScholarlyArticle",
"name": "A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/36787101",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42477"
}
},
{
"@type": "ScholarlyArticle",
"name": "Disturbed Complement Receptor Expression Pattern of B Cells Is Enhanced by Toll-like Receptor CD180 Ligation in Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2024-08-26",
"url": "https://questionsmedicales.fr/article/39273179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179230"
}
},
{
"@type": "ScholarlyArticle",
"name": "Purtscher-Like Retinopathy Induced by Diffuse Cutaneous Systemic Scleroderma.",
"datePublished": "2023-11-09",
"url": "https://questionsmedicales.fr/article/37950491",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/qjmed/hcad255"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Environnement et santé publique",
"item": "https://questionsmedicales.fr/mesh/D004778"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé publique",
"item": "https://questionsmedicales.fr/mesh/D011634"
},
{
"@type": "ListItem",
"position": 4,
"name": "Accidents",
"item": "https://questionsmedicales.fr/mesh/D000059"
},
{
"@type": "ListItem",
"position": 5,
"name": "Prévention des accidents",
"item": "https://questionsmedicales.fr/mesh/D000056"
},
{
"@type": "ListItem",
"position": 6,
"name": "Sécurité",
"item": "https://questionsmedicales.fr/mesh/D012449"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gestion de la sécurité",
"item": "https://questionsmedicales.fr/mesh/D017751"
},
{
"@type": "ListItem",
"position": 8,
"name": "Fiches techniques sur la sécurité des substances",
"item": "https://questionsmedicales.fr/mesh/D063967"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fiches techniques sur la sécurité des substances - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fiches techniques sur la sécurité des substances",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fiches techniques sur la sécurité des substances",
"description": "Comment identifier une substance dangereuse ?\nQuels tests pour évaluer la toxicité d'une substance ?\nComment évaluer l'exposition à une substance ?\nQuels indicateurs de dangerosité ?\nComment reconnaître une intoxication ?",
"url": "https://questionsmedicales.fr/mesh/D063967?mesh_terms=Scleroderma,+Diffuse&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fiches techniques sur la sécurité des substances",
"description": "Quels symptômes d'une exposition chimique ?\nComment se manifeste une intoxication aiguë ?\nQuels signes d'allergie à une substance ?\nQuels symptômes d'une exposition prolongée ?\nComment reconnaître une brûlure chimique ?",
"url": "https://questionsmedicales.fr/mesh/D063967?mesh_terms=Scleroderma,+Diffuse&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fiches techniques sur la sécurité des substances",
"description": "Comment prévenir les accidents chimiques ?\nQuelles mesures de sécurité en laboratoire ?\nComment stocker les substances dangereuses ?\nQuelles formations pour le personnel ?\nComment gérer les déchets chimiques ?",
"url": "https://questionsmedicales.fr/mesh/D063967?mesh_terms=Scleroderma,+Diffuse&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fiches techniques sur la sécurité des substances",
"description": "Quel traitement pour une intoxication ?\nComment traiter une brûlure chimique ?\nQuels soins pour une irritation cutanée ?\nComment gérer une exposition par inhalation ?\nQuel suivi après exposition à une substance ?",
"url": "https://questionsmedicales.fr/mesh/D063967?mesh_terms=Scleroderma,+Diffuse&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fiches techniques sur la sécurité des substances",
"description": "Quelles complications d'une exposition chimique ?\nQuels effets à long terme d'une intoxication ?\nComment les substances affectent-elles la reproduction ?\nQuelles maladies liées à l'exposition professionnelle ?\nQuels risques psychologiques liés à l'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D063967?mesh_terms=Scleroderma,+Diffuse&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fiches techniques sur la sécurité des substances",
"description": "Quels facteurs augmentent le risque d'intoxication ?\nComment l'environnement influence-t-il le risque ?\nQuels comportements à risque ?\nQuel rôle joue la formation dans la prévention ?\nComment les antécédents médicaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D063967?mesh_terms=Scleroderma,+Diffuse&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier une substance dangereuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Vérifiez les étiquettes, les fiches de données de sécurité et les pictogrammes de danger."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer la toxicité d'une substance ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests in vitro et in vivo, ainsi que des études épidémiologiques, sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'exposition à une substance ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez des méthodes de surveillance environnementale et des questionnaires d'exposition."
}
},
{
"@type": "Question",
"name": "Quels indicateurs de dangerosité ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indicateurs incluent la toxicité aiguë, la corrosivité et la réactivité."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une intoxication ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez les symptômes cliniques et les antécédents d'exposition à la substance."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une exposition chimique ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des nausées, des vertiges, des irritations cutanées."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une intoxication aiguë ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des troubles respiratoires, des convulsions ou un coma."
}
},
{
"@type": "Question",
"name": "Quels signes d'allergie à une substance ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des éruptions cutanées, des démangeaisons et des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une exposition prolongée ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes chroniques peuvent inclure des troubles neurologiques et des cancers."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une brûlure chimique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les brûlures chimiques se manifestent par des rougeurs, des cloques et des douleurs."
}
},
{
"@type": "Question",
"name": "Comment prévenir les accidents chimiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Formez le personnel, utilisez des équipements de protection et suivez les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles mesures de sécurité en laboratoire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez des hottes, portez des gants et des lunettes de protection, et suivez les procédures."
}
},
{
"@type": "Question",
"name": "Comment stocker les substances dangereuses ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Stockez-les dans des contenants appropriés, étiquetés et dans des zones ventilées."
}
},
{
"@type": "Question",
"name": "Quelles formations pour le personnel ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Formez le personnel sur les risques, les procédures d'urgence et l'utilisation des EPI."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets chimiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivez les réglementations locales pour le tri, le stockage et l'élimination des déchets."
}
},
{
"@type": "Question",
"name": "Quel traitement pour une intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la substance, mais peut inclure des antidotes et des soins de soutien."
}
},
{
"@type": "Question",
"name": "Comment traiter une brûlure chimique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rincez immédiatement la zone touchée à l'eau et consultez un professionnel de santé."
}
},
{
"@type": "Question",
"name": "Quels soins pour une irritation cutanée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Nettoyez la zone affectée et appliquez des crèmes apaisantes ou des antihistaminiques."
}
},
{
"@type": "Question",
"name": "Comment gérer une exposition par inhalation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éloignez la personne de la source, administrez de l'oxygène et surveillez les signes vitaux."
}
},
{
"@type": "Question",
"name": "Quel suivi après exposition à une substance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical est essentiel pour détecter d'éventuels effets à long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications d'une exposition chimique ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des maladies respiratoires chroniques et des cancers."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme d'une intoxication ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets neurologiques, hépatiques ou rénaux peuvent survenir après une intoxication."
}
},
{
"@type": "Question",
"name": "Comment les substances affectent-elles la reproduction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines substances peuvent causer des malformations congénitales ou des infertilités."
}
},
{
"@type": "Question",
"name": "Quelles maladies liées à l'exposition professionnelle ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies comme l'asthme, la dermatite et des cancers peuvent être liées à l'exposition."
}
},
{
"@type": "Question",
"name": "Quels risques psychologiques liés à l'exposition ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition peut entraîner des troubles anxieux, dépressifs ou des stress post-traumatiques."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'intoxication ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'état de santé, et l'exposition professionnelle fréquente."
}
},
{
"@type": "Question",
"name": "Comment l'environnement influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "La pollution, la proximité des sites industriels et les conditions de travail augmentent le risque."
}
},
{
"@type": "Question",
"name": "Quels comportements à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le non-port d'EPI, la consommation d'alcool et le non-respect des protocoles de sécurité sont risqués."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la formation dans la prévention ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une formation adéquate réduit les risques d'accidents et améliore la gestion des urgences."
}
},
{
"@type": "Question",
"name": "Comment les antécédents médicaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies respiratoires ou dermatologiques augmentent le risque d'effets néfastes."
}
}
]
}
]
}
Patients with diffuse cutaneous systemic sclerosis (dcSSc) frequently show spontaneous improvement of skin fibrosis. Our aim was to examine whether an improvement in skin fibrosis predicts lower likel...
Patients from the European Scleroderma Trials and Research (EUSTAR) cohort with dcSSc, baseline modified Rodnan skin score (mRSS) ≥7, and valid mRSS at 12±3 months follow up were included. Regression/...
Of 1257 included patients, 883 (70.2%) were stable, 282 (22.4%) regressive, and 92 (7.3%) progressive. Regressive patients, adjusted for baseline mRSS, baseline immunosuppression, baseline FVC, and di...
We found that regression of skin fibrosis is associated with a lower probability of lung progression and better survival at follow up. The link between the disease course of skin and lung fibrosis in ...
This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc)....
A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background tr...
The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.888 v...
A benefit of lenabasum in dcSSc was not demonstrated. Most patients were treated with background IST, and treatment with mycophenolate mofetil in particular was associated with better outcomes. These ...
We undertook this study to explore the efficacy, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc)....
NOVESA was a 24-week, multicenter, phase IIa, double-blind, placebo-controlled study. Adults with dcSSc were randomized to oral ziritaxestat 600 mg once daily or matching placebo. The primary efficacy...
Patients were randomized to ziritaxestat (n = 21) or placebo (n = 12). Reduction in MRSS was significantly greater in the ziritaxestat group versus the placebo group (-8.9 versus -6.0 units, respectiv...
Ziritaxestat resulted in significantly greater reduction in MRSS at week 24 than placebo; no new safety signals emerged. Biomarker analysis suggests ziritaxestat may reduce fibrosis. Modulation of the...
Autoantibody production is a hallmark of systemic sclerosis (SSc) and the most extensively studied role of B cells in the pathogenesis of the disease. However, the potential involvement of innate immu...
We report a rare case of Purtscher-like retinopathy related to systemic sclerosis, presented unprecedently an ultra-widefield optical coherence tomography angiography image for this combination, and s...
Keloidal scleroderma is a variant of scleroderma that presents as firm keloidal nodules or plaques. Due to the similarity in morphology and pathology, it is often distinguished from a hypertrophic sca...
Scleroderma is a systemic inflammatory disorder that can compromise the gastrointestinal tract in up to 90% of patients....
The purpose of this work is to characterize esophageal, gastric, and intestinal compromise in patients with scleroderma by means of minimally invasive methods and its association with symptoms and sev...
Patients with systemic sclerosis were recruited according to the criteria of the American College of Rheumatology. The study of digestive involvement was carried out on four consecutive days: esophage...
A total of 30 patients were included, with an average age of 52.7 years and 93% women. Average disease evolution duration was 6.5 years, 70% with limited variety. Rodnan averaged 12 points, being high...
Gastrointestinal involvement in patients with scleroderma is frequent and is observed regardless of the symptoms and clinical characteristics of the latter, except for skin involvement....
Systemic sclerosis is a systemic connective tissue disease whose main pathophysiological mechanism is a progressive fibrosis of internal organs and skin leading to thickening and induration. Blood ves...
[This corrects the article DOI: 10.3389/fimmu.2024.1351675.]....
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune d...